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SUMMARY
Adrenal insufficiency is managed by hormone
replacement therapy, which is far from optimal;
the ability to generate functional steroidogenic cells
would offer a unique opportunity for a curative
approach to restoring the complex feedback regu-
lation of the hypothalamic-pituitary-adrenal axis.
Here, we generated human induced steroidogenic
cells (hiSCs) from fibroblasts, blood-, and urine-
derived cells through forced expression of steroido-
genic factor-1 and activation of the PKA and LHRH
pathways. hiSCs had ultrastructural features resem-
bling steroid-secreting cells, expressed steroido-
genic enzymes, and secreted steroid hormones in
response to stimuli. hiSCs were viable when trans-
planted into the mouse kidney capsule and intra-ad-
renal. Importantly, the hypocortisolism of hiSCs
derived from patients with adrenal insufficiency
due to congenital adrenal hyperplasia was rescued
by expressing the wild-type version of the defective
disease-causing enzymes. Our study provides an
effective tool with many potential applications for
studying adrenal pathobiology in a personalized
manner and opens venues for the development of
precision therapies.
INTRODUCTION
The adrenal cortex is a major steroid-producing organ, secreting
glucocorticoids under the control of adrenocorticotropic hor-
mone (ACTH), secreted by the anterior pituitary gland, and min-
eralocorticoids under the control of the renin-angiotensin
system. Glucocorticoids affect carbohydrate metabolism and
mediate the mammalian stress response, and mineralocorti-
coids control blood volume and salt homeostasis. Primary or
secondary adrenal insufficiency (AI) results from adrenal failure
or impairment of the hypothalamic-pituitary axis, respectively.
In both cases, the cortex fails to secrete sufficient amounts of
glucocorticoids and adrenal androgens, but in primary AI, the
clinical consequences of aldosterone deficiency make this a
more lethal condition. The most frequent cause of primary AI is
autosomal recessive congenital adrenal hyperplasia (CAH),
which results from defects in enzymes involved in steroid biosyn-
thesis (Merke and Bornstein, 2005). Patients with AI need
life-long management with exogenous steroids: this can be
challenging, because no drug suitably mimics the diurnal pattern
of cortisol, and objective variables measuring the quality of
replacement therapy are lacking. Fine-tuning of replacement
therapy leaves only a narrow margin for improvement: under-
replacement can result in severe impairment of well-being and
incipient crisis, whereas even subtle, chronic over-replacement
has the potential to contribute to excess morbidity, including
obesity, osteoporosis, hypertension, and impaired glucose toler-
ance. Therefore, better treatment solutions are urgently needed
(Bornstein et al., 2016).
The ability to generate donor-specific and functional adreno-
cortical-like cells would facilitate: (1) the next generation of
cell-based treatments for AI; (2) the modeling of adrenal-specific
diseases; and (3) the testing of personalized interventions on
cells derived from patients.
Cells with an adrenocortical-like phenotype have never been
obtained in a patient-specific manner; moreover, previous at-
tempts have resulted in cells with very limited steroidogenic po-
tential (Crawford et al., 1997) or have used lines of embryonic
1236 Cell Reports 22, 1236–1249, January 30, 2018 ª 2018 The Authors.
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stem cells (Jadhav and Jameson, 2011; Yazawa et al., 2011),
mesenchymal stem cells (Gondo et al., 2004, 2008; Mazilu
and McCabe, 2011a; Tanaka et al., 2007; Wei et al., 2012; Ya-
zawa et al., 2006, 2009, 2010), and induced pluripotent stem
cells (iPSCs) (Sonoyama et al., 2012). The prerequisite of all
these studies was the forced expression of steroidogenic fac-
tor-1 (SF1), a master regulator of adrenogonadal development
and function encoded by nuclear receptor subfamily 5, group
A, member 1 (NR5A1). SF1 is a true effector of cell fate as it ini-
tiates a genetic program driving embryonic mesenchymal cells
toward a steroidogenic phenotype/lineage (Schimmer and
White, 2010), and SF1 mutations can result in adrenal insuffi-
ciency (Achermann et al., 2001). Other than SF1, additional
transcription factors (TFs), such as wilms tumor 1 (WT1),
CBP/p300-interacting transactivator 2 (CITED2), pre-B cell
leukemia transcription factor 1 (PBX1), and dosage-sensitive
sex reversal, adrenal hypoplasia critical region, on chromo-
some X, gene 1 (DAX1) have been shown to be key determi-
nants of adrenal cortex development (Yates et al., 2013).
Moreover, multiple pathways have been implicated in the
fine-tuned regulation of adrenocortical development, zonation,
and self-renewal (Lerario et al., 2017).
Here, we show an efficient protocol to reprogram, through
stable expression of SF1 and activation of the protein kinase
A (PKA) pathway and in the presence of luteinizing-hormone-
releasing hormone (LHRH), easily accessible sources of cells
from humans (blood, skin, and urine), resulting in human
induced steroidogenic cells (hiSCs). These hiSCs expressed
steroidogenic enzymes and secreted cortisol in a stimulus-
dependent manner. hiSCs could be efficiently exploited to study
donor-specific disease pathobiology and to test interventions,
such as restoration of eucortisolism in hiSCs from CAH patients.
Moreover, as a first step to assess whether hiSCs can be a viable
option for the development of cell-based treatments for AI, we
performed pilot in vivo experiments proving the viability of hiSCs
after transplantation into the adrenal glands and under the
kidney capsule of mice. These experiments pave the way for
further testing of hiSCs in suitable rodent models of AI, such as
double adrenalectomised rats (Balyura et al., 2015; Ruiz-Babot
et al., 2015).
RESULTS
Establishment of Human Primary Cultures from
Different Cell Sources
Primary cultures of human urine-derived stem cells (USCs), late-
outgrowth endothelial progenitor cells (L-EPCs), and fibroblasts
were initially established from healthy donors (Figure S1).
Because L-EPCs are phenotypically indistinguishable from
bone-marrow-derived endothelial cells (BMECs) (Yoder et al.,
2012), the latter were also used in our experiments.
Generation of hiSCs by Direct Lineage Conversion
Lentiviral vectors encoding SF1 and other TFs (PBX1, DAX1,
WT1, and CITED2) were used to infect human primary cells.
The vectors co-express GFP bicistronically and contain a
mammalian resistance cassette, which was used for selection
(Figure S2A). Cells were transduced according to the schematic
in Figure 1A and as reported in the Experimental Procedures.
The expression of the steroidogenic acute regulatory protein
(STAR) was used as a readout for initial experiments; STAR me-
diates the transfer of cholesterol from the outer to the inner mito-
chondrial membrane, where it is cleaved to pregnenolone and is
therefore indispensable and rate limiting for the synthesis of ste-
roids. Transduction of SF1, indeed, induced the expression of
STAR (Figure 1B).
Other TFs are involved in adrenocortical development and
self-renewal, chiefly PBX1, DAX1, WT1, and CITED2 (Yates
et al., 2013). RT-PCR analyses showed that PBX1, DAX1, and
CITED2, but not SF1, were expressed at the mRNA level in the
four cell types before reprogramming, whereas WT1 was ex-
pressed in L-EPCs and BMECs (Figure S2B). Unlike SF1, forced
expression of the other TFs either alone (Figure 1B) or in combi-
nation did not induce STAR expression and neither did they
enhance the effect of SF1 alone (Figure 1C). Lentiviral delivery
of SF1 did not significantly alter the endogenous expression
levels of PBX1, WT1, DAX1, and CITED2; however, it reduced
the expression of WT1 in L-EPCs (Figure S2B). These data
demonstrate that SF1 alonewas able to induceSTAR expression
in human cells. Interestingly, on forced expression of SF1, cells
(irrespective of the source) had a lower proliferation rate, as
Figure 1. Conversion of Human Urine-Derived Stem Cells into Steroidogenic Cells
(A) Schematic illustrating our strategy for urine collection, processing, and reprogramming. Urine-derived cells (USCs) were cultured in specific media, and type-II
colonies amplified and characterized through flow cytometry. Then they were either banked or expanded for experiments. USCs were infected at passage two
with either a lentivirus encoding a transcription factor (TF) within an IRES-GFP vector, a combination of TFs, or mock infected (MOI = 200). Cells were treated with
8-br-cAMP (100 mM) unless stated otherwise and kept in culture for at least eight days before analyses.
(B) RT-PCR showing STAR expression on forced expression of each TF. The expression of exogenous SF1, PBX1, WT1, DAX1, and CITED2 was assessed by
RT-PCR using primers encompassing the coding- and vector- specific regions. Human adrenal cDNA was used as a positive control for endogenous STAR
expression and, along with non-template control (NTC), as a negative control for exogenous TF expression.
(C) qRT-PCR analyses of STAR expression on forced expression of SF1 with each TF (upper panel) and of SF1 with or without a combination of TFs (lower panel).
(D) Western blot analyses of PCNA and GAPDH expression in hiSCs and mock-reprogrammed USCs from four independent donors eight days after re-
programming (top left panels); cell counting (bottom left panels) and representative images (right panels) of hiSCs obtained from USCs and fibroblasts versus
mock-reprogrammed cells. Scale bars, 50 mm.
(E) qRT-PCR analyses of STAR expression on forced expression of SF1 with or without the indicated treatments, started the day after infection for seven days.
CNT, cells infected with empty control vector.
(F) qRT-PCR (upper panel) and RT-PCR (lower panels) analyses of STAR and SF1 expression after reprogramming USCs at different MOI of SF1 or empty control
lentiviral vector (CNT).
(G) Morphological changes on SF1 overexpression in USCs eight days post-infection. Scale bars, 20 mm.
(H) Electron microscopy images of USCs and USCs eight days after reprogramming. Arrows point to mitochondria. Nu, nucleus.
Scale bars, 2 mm (left panels) and 1 mm (right panels). Data in (C)–(F) are represented as mean ± SEM, nR 3. See also Figures S1 and S2.
1238 Cell Reports 22, 1236–1249, January 30, 2018
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assessed by the expression of proliferating cell nuclear antigen
(PCNA) and direct cell counting (Figure 1D), and became prolif-
eration arrested three to five days after infection. Cells with this
seemingly terminal differentiation phenotype have been main-
tained for at least two months in culture without loss of viability.
Several treatments were then tested to assess which, if any,
would consistently induce an incremental change in the expres-
sion of STAR. Activators of PKA, such as dibutyryl cyclic AMP
(db-cAMP) or 8-bromo-cyclic AMP (8-br-cAMP), were the most
potent inducers of STAR expression, whereas angiotensin II
(AngII), potassium (K+), and all-trans retinoic acid (ATRA) had
no effect (Figure 1E). Based on these results, 8-br-cAMP
(100 mM) was selected to be included in the reprogramming
protocol on day two after SF1 transduction.
We next evaluated the dose of SF1 delivered after lentiviral
infection and its effect on STAR expression: SF1-expressing
cells, but not controls, increased STAR levels in a multiplicity of
infection (MOI)-dependent manner (Figure 1F). Based on these
results, an MOI of 200 was used in subsequent experiments.
Morphologically, all cell types similarly underwent a dramatic
change of shape 48–72 hr post-transduction, acquiring an irreg-
ular stellate morphology with concomitant reduction of the cyto-
plasmic volume (Figure 1G; Figure S2D; Movie S1). Despite the
neuronal-like morphology, absence of mRNA expression of the
neuroectoderm marker paired box gene 6 (PAX6) (Zhang et al.,
2010) and the dopaminergic neuronal marker tyrosine hydroxy-
lase (TH) (Lewis et al., 1993) ruled out that these cells could be
neuronal-like functionally (Figure S2C).
Electron microscopy images showed larger mitochondria with
a densely packed inner mitochondrial membrane in USCs-hiSCs
in comparison with controls (Figure 1H). In addition, reprog-
rammed cells had an increased expression of the mitochondrial
import receptor subunit translocase of outer mitochondrial
membrane 20 (TOM20) compared with controls, as assessed
by western blotting (Figure S2E). Finally, qRT-PCR analyses
showed that reprogrammed cells also had enhanced expression
of mitochondrial ribosomal RNA 12S (Figure S2F). Together,
these data suggest that reprogrammed cells potentially are
endowed with higher metabolic activity typical of steroidogenic
cells.
hiSCs Possess Gene Expression Patterns and Functions
Specific for Steroidogenic Cells
After cholesterol transfer, steroid hormones are produced after a
cascade involving steroidogenic enzymes and intermediate me-
tabolites (Figure 2A). We next assessed the expression of ste-
roidogenic enzymes by RT-PCR eight days after reprogramming
USCs. As shown in Figure 2B, we detected de novo expression
or upregulation of all steroidogenic enzymes analyzed in hiSCs in
comparison to cells infected with control lentiviruses. We found
expression of cytochrome B5 (CYB5) in both control and reprog-
rammed cells, while we could not detect expression of sulfo-
transferase 2A1 (SULT2A1), which is in agreement with
the absence of DHEA-S secretion (see below). Fibroblasts,
L-EPCs, and BMECs showed an identical pattern of steroido-
genic enzyme induction (Figure S3A). Concomitant expression
of SF1, PBX1, WT1, DAX1, and CITED2 (five TFs) enhanced
CYP17A1 and HSD3B2 expression, whereas they decreased
CYP21A2 expression and did not change CYP11A1 expression.
Four TFs without SF1 had a negligible effect on the expression of
steroidogenic enzymes (Figure S3B). Moreover, the expression
of steroidogenic enzymes was enhanced by 8-br-cAMP (Fig-
ure S3C) as was the expression of STAR. Reprogrammed cells
did not express the testis marker doublesex and mab-3-related
transcription factor 1 (DMRT1) and expressed the ovary marker
estrogen receptor alpha (ESR1) at very low levels (ESR1 is also
expressed in the adrenal gland, although at a lower level
compared with the ovaries) (Figure S3D). Moreover, luteinizing
hormone receptor (LHR) was undetectable in control USCs
and was expressed at a very low level in reprogrammed cells
compared with the adrenal gland (Figure S3D). These data
may suggest a preponderance of adrenocortical-like cells versus
a gonadal-like phenotype in reprogrammed cells.
Analyses of hiSCs at the protein level (where specific anti-
bodies were available) confirmed de novo expression of STAR,
exogenous SF1, steroidogenic enzymes, as well as the absence
of SULT2A1, both by western blot (Figure 2C) and immunocyto-
chemistry (Figure 2D; Figure S3E). Differentiation of several in-
dependent USC colonies from the same donor or from different
donors (either healthy or with congenital adrenal disease)
showed similar reprogramming efficiencies as assessed by the
expression of STAR protein (Figure S3F), STAR mRNA expres-
sion, as well as expression of steroidogenic enzymes (data not
shown).
We next assessedwhether urine-derived hiSCswere hormone
producing by analyzing cell supernatants of cells eight days after
reprogramming using liquid chromatography-tandem mass
spectrometry (LC-MS/MS). As shown in Figure 3A, a very signif-
icant increase or de novo production of steroid hormones and
precursors was observed in the medium in hiSCs versus control
cells. Dehydroepiandrosterone sulfate (DHEA-S) was not
detected, which is in keeping with the absence of SULT2A1 (Fig-
ures 2B and 2C). hiSCs had a lower and, despite several
interventions, irreversible (Figure S4) cortisol:cortisone ratio
compared with human serum or medium from adrenocortical
carcinoma H295R cells (Vogeser et al., 2001; Xing et al., 2011).
Overall, these results showed that hiSCs secrete a full reper-
toire of adrenocortical hormones, irrespective of the cell source,
Figure 2. Gene Expression Profile of Reprogrammed USCs
(A) Steroidogenic pathway in the adrenal cortex leading to the production of cortisol and aldosterone.
(B) RT-PCR expression analyses of STAR, steroidogenic enzymes, SULT2A1, GAPDH, and ACTIN in cells infected with SF1 or control (CNT) lentiviruses after
eight days. Human adrenal cDNA was used as a positive control. All cells were treated with 8-br-cAMP. NTC, no template control.
(C) Western blot analyses of STAR, SF1, steroidogenic enzymes, SULT2A1, andGAPDH expression in USCs and in USCs infected with SF1 or control lentiviruses
(mock) after eight days. Human adrenal lysate was used as a positive control. All cells were treated with 8-br-cAMP.
(D) Immunostaining of SF1 (upper panels) and STAR (lower panels) in mock-reprogrammed and reprogrammed USCs. Scale bars, 20 mm; insets, 5 mm.
Data in (B) are represented as mean ± SEM, nR 3. See also Figure S3.
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Figure 3. Hormone Production in Reprogrammed USCs
(A) LC-MS/MS analyses of steroid in the media of reprogrammed versus control USCs after eight days. N.D., non-detected.
(B) RT-PCR showing MC2R and MRAP expression in controls and reprogrammed USCs after eight days.
(C) Cortisol production in control and hiSCs treated with 1 mM ACTH or 100 mM 8-br-cAMP for eight days.
(D) qRT-PCR analyses of STAR, CYP11B1, and CYP11B2 expression in controls and reprogrammed USCs treated with LH and WNT4 for eight days. Cortisol
secretion is reported in the right panel.
(E) qRT-PCR analyses of STAR expression in USCs treated with LHRH, bombesin, and ACTH. Effect of [D-Trp6]-LHRH and bombesin on cortisol production (left)
and in cell viability using CC8 assay.
(F) Schematic illustrating the final protocol employed to generate hiSCs.
Data in (A) and (C)–(E) are represented as mean ± SEM, nR 3. See also Figure S4.
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as hiSCs from fibroblasts and L-EPCs had a similar steroid pro-
file (data not shown).
ACTH is the main stimulator of cortisol release in adult adrenal
glands through binding to its receptor MC2R, leading to an
activation of PKA signaling (Ruggiero and Lalli, 2016). Gene
expression analyses for MC2R and its accessory protein
MRAP detected both transcripts in hiSCs; these transcripts
were absent in controls (Figure 3B). Cortisol was undetectable
in primary cultures before reprogramming or in mock-reprog-
rammed cells and was produced at low levels in untreated
hiSCs; however, a significant and comparable increase was
detected after stimulation with ACTH or 8-br-cAMP (Figure 3C).
These results demonstrated the functionality of hiSCs in regards
to their responsiveness to external stimuli, both physiological
(ACTH) and pharmacological (8-br-cAMP).
Recently, b-catenin activation has been shown to promote a
zona glomerulosa phenotype; moreover, the action of b-catenin
was counteracted by PKA activation, which instead promoted
a zona fasciculata phenotype (Drelon et al., 2016). To assess
whether the activation of b-catenin had any effect on the
expression of zonal-specific markers, reprogrammed cells
were treated with recombinant WNT4 (alongside recombinant
LH). We found no significant changes in the expression of
CYP11B1, CYP11B2, and STAR or on cortisol secretion (Fig-
ure 3D). Finally, it has been reported that the LHRH analog
[D-Trp6]-LHRH (Balyura et al., 2015) and bombesin (Malendo-
wicz et al., 1995) acutely stimulate adrenal glucocorticoid
release. Both LHRH and bombesin, while not affecting STAR
mRNA levels (Figure 3E), significantly increased cortisol produc-
tion in hiSCs; however, only LHRH significantly increased the
metabolic activity and lifespan of hiSCs in culture (Figure 3E).
Therefore, in our final reprogramming protocol to generate
hiSCs, schematized in Figure 3F, [D-Trp6]-LHRH was included
at a concentration of 1 mM starting from day two after SF1
infection.
hiSCs Are Viable When Transplanted into the Mouse
Adrenal Gland or Kidney Capsule
To test cell viability in vivo, hiSCs from USCs were implanted
in mice using three different procedures, schematized in Fig-
ure S5A: first, via ectopic implantation under the kidney capsule
as free cells with fibrinogen/thrombin mixture; second, as ortho-
topic (intra-adrenal) implants with fibrinogen/thrombin mixture;
and third, via ectopic implantation under the kidney capsule of
cells embedded into alginate. No signs of necrosis or apoptosis
were observed when cells were directly implanted under the kid-
ney capsule and analyzed after one and three weeks (Figures
4A–4C). In implanted cells, nuclear SF1 staining and expression
of steroidogenic enzymes, such as CYP11A1, were observed in
hiSCs, but not in control cells (Figures 4E–4L). Interestingly, at
three weeks post-transplantation, blood vessels could be de-
tected in hiSC, but not control, xenografts (Figure 4C, quantifica-
tion in Figure 4D), suggesting neovascularization.
To assess differentiation in vivo, cells were implanted ortho-
topically 24 hr post-infection, at a time when steroidogenic en-
zymes are not expressed at either the mRNA or the protein level
(data not shown); 8-br-cAMP and LHRH were also omitted. His-
tological analyses of adrenal gland explants after one week,
showed no signs of fibrosis or inflammation (Figures 4M and
4N). To localize transplanted cells in the context of host adreno-
cortical cells, sections were immunostained with a GFP antibody
(Figures 4O–4Q); the steroidogenic potential and in vivo differen-
tiation of hiSCs was further assessed by their expression of
CYP17A1, an enzyme that is epigenetically silenced in adult
mice (Missaghian et al., 2009); we observed CYP17A1 staining
in transplanted cells, but not in mouse adrenocortical cells (Fig-
ures 4R–4T).
hiSCs embedded in alginate and cultured in vitro had the same
gene expression profile and hormonal secretion as monolayer
hiSCs (not shown); however, histological analyses of explants
(after one week and three weeks) showed features of anuclear
necrosis in most transplanted cells with evident signs of karyol-
ysis (nuclear fading) and karyorrhexis (nuclear fragmentation)
(Figure S5B). The same was observed in alginate slabs
embedded with control cells (data not shown). These experi-
ments demonstrate the viability of hiSCs in two out of three
experimental settings and pave the way for transplantation ex-
periments on a larger scale to assess hiSCs function in murine
models of AI, in which a much greater number of reprogrammed
cells are needed. However, hiSCs generated from all cell sources
Figure 4. Transplantation of hiSCs into Mouse Kidney and Adrenal Gland
(A) hiSCs implanted directly under the kidney capsule as a fibrin clot.
(B–D) H&E analyses of cells directly implanted under the kidney capsule as a fibrin clot. Blood vessels were observed to develop in explants after three weeks
when hiSCs were implanted directly under the kidney capsule as a fibrin clot (C, count in D).
(E–H) Expression of SF1 in controls (E and F) and hiSCs (G and H) implanted directly under the kidney capsule.
(I–L) Expression of CYP11A1 in controls (I and J) and hiSCs (K and L) implanted directly under the kidney capsule.
(M and N) H&E analyses of a mouse adrenal gland transplanted for one week with USCs infected with SF1 24 hr earlier at lower (M) and higher (N) magnification.
hiSCs can be observed at the cortex/medulla boundary (arrow in N).
(G–T) Cells transplanted into the adrenal can be visualized by the expression of GFPwith immunohistochemistry (O and P), GFP indirect immunofluorescence (Q),
or by their expression of CYP17A1 via immunohistochemistry (R–T). Arrows in (O)–(Q) and (S) point to transplanted cells. CYP17A1 is absent in mouse adrenal
cortex (R and T). ZG, zona glomerulosa; ZF, zona fasciculata. Scale bars: 50 mm in (B), (C), (E), (G), (I), and (K); 25 mm in (F), (H), (J), (L), (N), (P), (Q), (S), (T); and
100 mm (M), (O), (R).
(U–W) Development of an inducible system aimed at generating unlimited amounts of hiSCs. (U) Schematic of the cumate vector generated to infect USCs. In
repressed configuration, CymR repressor strongly binds to the cumate operator site (CuO), downstream of the CMV5 promoter. When cumate is present, CymR
is released, which enables transgene expression. (V) USCs were infected with the cumate vector, selected with puromycin, and then treated with cumate or
vehicle. Cells underwent similar morphologic changes to those observed in Figure 1G. Scale bars, 50 mm; inset, 20 mm. (W) qRT-PCR analyses of
STAR expression after seven days of treatment with increasing concentration of cumate, showing induction dose dependently. Data in (W) are represented as
mean ± SEM, n = 3.
See also Figure S5.
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were proliferation arrested (Figure 1D), and although we have
been unable to find factors promoting proliferation concomi-
tantly with the maintenance of a functional steroidogenic pheno-
type, a cumate-inducible system was successfully developed,
allowing us to generate expandable populations of hiSCs (Fig-
ures 4U–4W).
hiSCs from CAH Patients Show Impaired
Steroidogenesis, and Their Hypocortisolism Can Be
Reversed through Restoration of Enzymatic Function
Currently available immortalized cell lines (mainly obtained from
adrenocortical carcinomas) express certain steroidogenic en-
zymes at low levels, produce an incomplete steroid profile, and
have genetic backgrounds specific for the donors they were
derived from. Although animal models of CAH have been gener-
ated (Bornstein et al., 1999; Mullins et al., 2009), it has not been
possible to design disease models involving human steroido-
genic cells. For this reason, we evaluated the steroid profile of
hiSCs obtained from patients with CAH (Table 1). CAH due to
21-hydroxylase deficiency (21-OH) is a common autosomal
recessive disorder caused by defects in the CYP21A2 gene. Pa-
tient #1 harbored one of the most common mutations (p.I172N),
resulting in a simple virilizing form of CAH and a residual activity
of the enzyme of 1%–10% (Hsu et al., 1996). LC-MS/MS steroid
analyses of parallel differentiations of two independent USCs
colonies obtained from patient #1 showed an accumulation
of metabolites upstream of the 21-OH enzyme, including 17
hydroxyprogesterone, 17 hydroxypregnenolone, and adrenal
androgens and a reduction of those downstream, including
DOC and cortisol, as compared with healthy donor controls (Fig-
ure 5A). Lentiviral delivery of wild-type CYP21A2 significantly
increased cortisol levels in a dose-dependent manner concom-
itantly to a reduction of 17-hydroxyprogesterone, 17-hydroxy-
pregnenolone, and testosterone (patient #1 in Figure 5B).
Furthermore, rescue of cortisol hypo-secretion was successfully
achieved in hiSCs established from other CAH patients with
diverse genetic mutations (Table 1; Figure 5C). These results
demonstrated that hiSCs derived from patients’ urine are also
excellent experimental models for monogenic congenital adre-
nal disorders and are amenable to personalized interventions
for treatment.
DISCUSSION
Donor- and disease-specific steroidogenic cells as surrogates
for disease modeling have been lacking up to now. More signif-
icantly, their use could be exploited for the development of cell-
based treatment modalities for AI.
We have shown that the use of a single cell fate regulator
(SF1/NR5A1), in conjunction with PKA and LHRH signaling,
can stably reprogram human adult skin-, blood-, and urine-
derived cells into hiSCs. Forced expression of other key TFs
involved in adrenogonadal differentiation, alone or in combina-
tion, was not sufficient to induce hiSCs, nor did their expression
with SF1 enhance reprogramming. However, given that there is
endogenous expression of DAX1, PBX1, CITED2, and WT1 in
non-reprogrammed cells, it is entirely possible that they partici-
pate in hiSC induction along with SF1, although the higher
dosages delivered by our constructs did not improve reprogram-
ming. Activation of the WNT pathway through WNT4 is associ-
ated with zona glomerulosa differentiation, which is prevented
by PKA activation (Drelon et al., 2016). Treatment of hiSCs
with recombinant WNT4 did not result in changes of zonal-
specific markers nor cortisol secretion; it is possible that, in our
experimental setting, forced-expression of SF1 bypasses key
differentiation events occurring physiologically at the capsule/
subcapsular region during the normal self-renewal/zonal specifi-
cation of the gland.
Fibroblasts are the preferred cell substrate for reprogramming,
but more recently, alternative cell types have also been used;
USCs are highly expandable, have self-renewal capacity, para-
crine properties, and multi-differentiation potential (Bharadwaj
et al., 2013; Guan et al., 2014) and have been used as substrates
for iPSC generation (Zhou et al., 2012). USC isolation is easy and
efficient; we were able to establish cultures with 75% efficacy for
one sample and 95% for a second sample, compared with 30%
efficacy for L-EPCs (100% for fibroblasts). USCs, L-EPCs, and
fibroblasts are all mesoderm derived, however, only USCs are
thought to originate from the intermediate mesoderm, a precur-
sor of the adrenocortical and nephritic primordium, which make
them an ideal substrate to generate mesodermal tissues, such
as adrenogonadal-like cells (Mazilu and McCabe, 2011b). Given
the importance of SF1 dosage during adrenal versus gonadal
specification (Bland et al., 2004; Val et al., 2007), further develop-
ment of inducible and tunable systems to modulate the expres-
sion of SF1 would likely facilitate a more specific adrenocortical
or gonadal induction during reprogramming. Gene expression
analyses of adrenocortical and gonadal markers already sug-
gested that our protocol might favor a more adrenocortical
phenotype (Figure S3D).
The functionality of hiSCs makes them an unmatched tool
to obtain surrogate adrenocortical cells for in vitro disease
modeling. With this in mind, we have derived hiSCs from patients
Table 1. Congenital Adrenal Hyperplasia Patients Enrolled in this
Study
Patient/Donor
Identification
Gene
Affected DNA Protein
Patient #1 CYP21A2 c.515T > A p.(Ile172Asn)
Patient #2 CYP21A2 c.955C > T p.(Gln319Stop)
Patient #3 STAR c.666delC p.(Thr223Leufs*98)
Patient #4 HSD3B2 NA NA
Patient #5 CYP11A1 c.940G > A p.(Glu314Lys)
c.990G > A
Patient #1 presents a simple virilizing form of CAH due to one of the most
common mutations in CYP21A2 (p.I172N). Patient #2 harbors a prema-
ture stop codon in CYP21A2 at glutamine 319 (p.Q319*), which has
been previously described as pathogenic. Patient #3 harbors a frameshift
mutation in the STAR protein (p. Thr223fs), leading to disruption of the
C-terminal START domain responsible for cholesterol binding and pro-
motion of the translocation of cholesterol to themitochondrial innermem-
brane. Patient #4 was diagnosed with HSD3B2 deficiency biochemically.
Patient #5 is compound heterozygous for two putative splicing mutations
in the CYP11A1 gene, which result in exon 5 skipping and a subsequent
frameshift (L.A.M., unpublished data).
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with CAH, showing an altered steroid profile. Importantly, the
decrease in cortisol production in hiSCs derived from CAH
patients was rescued on expression of the exogenous native
forms, irrespective of the defective steroidogenic enzyme.
USCs-hiSCs were shown to be viable in vivo when trans-
planted into mouse adrenal gland tissue and successfully
differentiate toward an adrenal-like lineage within the adrenal
tissue itself, as cells were implanted 24 hr post-infection
when steroidogenic enzymes are not expressed. Whether the
surrounding adrenal tissue favors differentiation remains to
be explored, as well as the long-term viability/functionality
and fate of transplanted cells. hiSCs implanted under the
mouse kidney capsule maintained the expression of steroido-
genic enzymes and showed well-vascularized tissue at the site
of transplantation after three weeks, suggesting viability of
those cells in vivo. Remarkably, vascularization was not
observed in control implants; this can be explained either by
the intrinsic ability of SF1 to regulate adrenocortical vascular
remodeling through the expression of angiopoietin-2 (Ferraz-
de-Souza et al., 2011) or by the very significant upregulation
of the potent pro-angiogenic tetraspartin CD9 in hiSCs de-
tected in a proteomic array in all cell sources (Figure S6).
CD9, also expressed in the normal adrenal, but with unknown
function (Nakamura et al., 2001), exerts its angiogenic action
via exosomes, where it is abundantly expressed (Andreu and
Ya´n˜ez-Mo´, 2014).
Sodium alginate has been used as a 3D scaffold for cell immo-
bilization/delivery in tissue engineering (Bidarra et al., 2014) and
might confer some immunoprotection (Llacua et al., 2016). How-
ever, hiSC viability was compromised on implantation; control
cells were also negatively affected, suggesting cell-specific
toxicity of alginate after grafting in our system (both hiSCs and
control cells embedded in alginate were viable and functional
in vitro).
Overall, these pilot transplantation experiments showed that
viability of hiSCs is affected by the transplantation protocol
used. Longer-term experiments with a yet-to-be determined
amount of cells would allow for careful assessment of: (1) the
number of cells needed to be able to detect cortisol (undetect-
able in our pilot experiments); (2) the time needed to become fully
functional; (3) their viability long term; and (4) their rescuing po-
tential in animal models of AI.
Novel approaches to treating AI are needed for a condition in
which mortality rates continue to be 2-fold higher than the
background population despite steroid replacement (Bergth-
orsdottir et al., 2006). Although newer steroid formulations
(e.g., Plenadren and Chronocort) are being developed to mimic
circadian rhythms more precisely, replacement remains inher-
ently limited in its responsiveness to physiological need. This
study paves the way for the development of alternative ap-
proaches to treat AI. For example, hiSCs could be implanted
intra-adrenally or encapsulated using immunoisolating cham-
bers, possibly after gene-editing in case of mono/oligogenic
disorders, as previously used in beta-cell transplantation (Desai
and Shea, 2017). To this end, USCs have recently been suc-
cessfully gene edited in a model of human muscle disease
(Kim et al., 2016). This will allow a curative cell replacement
therapy for patients with AI.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures.
Materials
All antibodies, plasmids, and primers used are listed in Supplemental Experi-
mental Procedures.
Cell Culture
Primary cultures of USCs, fibroblasts, and L-EPCs were isolated as previ-
ously described (Martin-Ramirez et al., 2012; Poliandri et al., 2017; Zhou
et al., 2012). BMECs were a kind gift of Dr. Egle Solito (Schweitzer et al.,
1997; Solito et al., 2000), and HEK293T lines were obtained from ATCC.
SF1-inducible cell lines were generated using a SparQ cumate switch
pCDH-CuO-MCS-IRES-GFP-EF1-CymR-T2A-Puro All-in-one inducible lenti-
vector (Cambridge Bioscience, Ltd.) expressing SF1. The detailed protocols
for the isolation of all cell types are provided in Supplemental Experimental
Procedures.
Lentiviral Production and Cell Reprogramming
Lentiviral particles were obtained as previously described (Cribbs et al., 2013)
with minor modifications. 60,000 cells per well of a six-well plate were infected
with lentiviral particles at a MOI of 200 with 8 mg/mL of polybrene (Millipore,
TR-1003-G). The medium was replaced after 12 hr, and treatments with
different molecules were started after two days. Cells were cultured for an
additional 5–10 days before analysis. Drug concentrations are detailed in Sup-
plemental Experimental Procedures.
Gene Expression Analysis
See Supplemental Experimental Procedures for details.
Immunoassays
Immunoblotting, immunocytochemistry, and immunohistochemistry were
performed as described previously (Guasti et al., 2011; Rodrı´guez-Asiain
et al., 2011). See Supplemental Experimental Procedures for details.
Hormone Quantification
Hormone quantification was performed using an ELISA Kit (Abcam, ab154996)
according to the manufacturer’s instructions and LC-MS/MS (Taylor et al.,
2017). See Supplemental Experimental Procedures for details.
Mitochondrial Morphology Studies
Electron microscopy was performed by the Nanovision Centre, Queen Mary
University of London, using standardized procedures.
Figure 5. Characterization of Urine-Derived hiSCs Established from Patients with CAH
(A) Comparison of steroidogenic profile of hiSCs established from patient #1 with CYP21A2mutation (CAH) versus healthy donors (CNT). The diagram on the left
shows the steroidogenic pathway with increased metabolites in patient #1 highlighted in green and decreased ones in red.
(B) Comparison of cortisol, 17-hydroxyprogesterone, 17-hydroxypregnenolone, and testosterone levels of hiSCs derived from patient #1 with or without
restoration of the wild-type form 21-OH. Cells were infected with two increasing amounts of lentiviral particles (31 and 35).
(C) Comparison of cortisol levels of hiSCs derived from patients (#2–#5) with several forms of CAH with or without restoration of the wild-type form of the
corresponding steroidogenic enzymes. RT-PCR analyses using primers encompassing coding- and vector-specific regions confirmed the expression of the
exogenous enzymes (lower panels). See also Table 1. Data are represented as mean ± SEM, nR 3.
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Animal Experiments
All animal experiments were performed in strict accordance with protocols
approved by the ethical board of Landesdirektion Sachsen, Germany (protocol
no. DD24-5131/354/28). Female 8-week-old C57BL/6 mice were obtained
from Charles River Laboratory. Two million cells were transplanted under the
kidney capsule and 5 3 105 cells concentrated in a total volume of 10 mL
were pipetted directly into the adrenal gland.
See Supplemental Experimental Procedures for details.
Collection of Urine Samples from Donors
This study has been performed under the ethical approval of the National
Health Service, Research Ethic Committee (NHS REC; reference: 13/LO/
0224). All patients involved were previously informed, and consent forms
were obtained before analysis of samples.
Protein Array of Human Reprogrammed Steroidogenic Cells
Protein array was performed by Sciomics, GmbH (Germany) using control and
eight-day reprogrammed hiSCs. See Supplemental Experimental Procedures
for details.
Data Analysis
Figures and tables were generated using Microsoft Excel, ImageJ, and Adobe
Photoshop.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7, and statistical
significance was determined using one-way ANOVA followed by Dunnet’s
multiple comparison test correction. A Student’s t test was performed when
only two means were compared. Significance: not significant (ns) p > 0.05;
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
DATA AND SOFTWARE AVAILABILITY
The accession number for the protein array data reported in this article is Men-
deley Data: https://doi.org/10.17632/x9rn9kcr3b.2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one movie and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.01.003.
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